<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621252</url>
  </required_header>
  <id_info>
    <org_study_id>PLN-74809-IPF-205</org_study_id>
    <nct_id>NCT05621252</nct_id>
  </id_info>
  <brief_title>Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)</brief_title>
  <acronym>PLN-74809</acronym>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pliant Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pliant Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, single -center, randomized, double-blind, placebo-controlled study to&#xD;
      evaluate type 1 collagen deposition in the lungs following once-daily treatment with&#xD;
      PLN-74809 for 12-weeks. This study is occurring at Massachusetts General Hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, single-center, randomized, double-blinded, placebo-controlled study to&#xD;
      evaluate type 1 collagen deposition in the lungs of participants with Idiopathic Pulmonary&#xD;
      Fibrosis (IPF) following once-daily (QD) treatment with 160 mg PLN-74809 for 12 weeks. The&#xD;
      study consists of an up to 28-day screening period, a 12-week treatment period, and a 2 week&#xD;
      (±3 days) post treatment follow-up period.&#xD;
&#xD;
      Approximately 12 eligible participants will be randomized in a 2:1 ratio (160 mg PLN-74809 vs&#xD;
      placebo; 8 receiving PLN-74809 and 4 receiving placebo) on Day 1 (Visit 3). Randomization&#xD;
      will be stratified by use of standard of care IPF therapy with pirfenidone or nintedanib.&#xD;
      PET/MRI scans will be conducted at Baseline and at Week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2022</start_date>
  <completion_date type="Anticipated">October 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>8 participants will be receive PLN-74809 and 4 participants will receive placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants with a change in Baseline of type 1 collagen in the lung following 12 weeks of treatment with PLN-74809, as assessed by changes from Baseline in 68Ga-CBP8 (PET)/(MRI) tracer uptake patterns</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety and Tolerability</measure>
    <time_frame>From screening period (up to 28 days) to treatment period of 12 weeks, to 2 weeks after last dose</time_frame>
    <description>Safety and tolerability of PLN-74809 as measured by the incidence of adverse events.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory 1</measure>
    <time_frame>12 weeks</time_frame>
    <description>Forced vital capacity (FVC): absolute FVC volume and FVC as percent of predicted as assessed by spirometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory 2</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patient-reported outcome (PRO): a visual analog scale (VAS) for cough severity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>PLN-74809</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 mg PLN-74809</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLN-74809</intervention_name>
    <description>160 mg PLN-74809</description>
    <arm_group_label>PLN-74809</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants, aged 40 years or older&#xD;
&#xD;
          -  Diagnosis of IPF, within 8 years prior to Screening&#xD;
&#xD;
          -  FVC % predicted ≥45%; historical FVC for entry in the study is permitted if within 1&#xD;
             month of screening&#xD;
&#xD;
          -  Diffusing capacity for carbon monoxide DLco (hemoglobin-adjusted) ≥30%; historical&#xD;
             DLco for entry in the study is permitted if within 1 month of Screening&#xD;
&#xD;
          -  Participants currently receiving treatment for IPF with nintedanib or pirfenidone are&#xD;
             permitted, if on a stable dose for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents&#xD;
             not approved for that indication by the FDA&#xD;
&#xD;
          -  Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC&#xD;
             ratio &lt;0.7 at Screening&#xD;
&#xD;
          -  Clinical evidence of active infection, including but not limited to bronchitis,&#xD;
             pneumonia, sinusitis that can affect FVC measurement or IPF progression&#xD;
&#xD;
          -  Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months&#xD;
             of Screening&#xD;
&#xD;
          -  Smoking of any kind within 3 months of Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sydney Montesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mass. General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Fromson</last_name>
    <phone>617-643-3260</phone>
    <email>cfromson@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Fromson</last_name>
      <phone>617-643-3260</phone>
      <email>CFROMSON@MGH.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Sydney Montesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

